77P Experience pooling control arms within a complex phase I drug-radiotherapy (RT) platform trial
Jamie B. Oughton, Sarah Brown(University of Leeds), Alastair Greystoke(Newcastle University), Mark A. Norris(University of Leeds), Stephen Harrow(Beatson West of Scotland Cancer Centre), Crispin T. Hiley(The Francis Crick Institute), J. Kendall, Ashley Horne(The Christie NHS Foundation Trust), P.H. Shaw(Velindre NHS Trust), Anthony J. Chalmers(Beatson West of Scotland Cancer Centre), O.A. Ojo(Obafemi Awolowo University), F. Walker(University of Leeds), Corinne Faivre‐Finn(University of Manchester), R.H. Phillip(University of Leeds), K. Franks(Leeds Teaching Hospitals NHS Trust)
Cited by 0
Related Papers
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
|New England Journal of Medicine|2007|1.1k